Home > Boards > US OTC > Biotechs >

Deltagen (DGEN)

DGEN RSS Feed
Add DGEN Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 11/11/2014 3:45:40 PM - Followers: 11 - Board type: Free - Posts Today: 0


 

             

Deltagen is a leading provider of drug discovery tools and services to the biopharmaceutical industry. Deltagen offers a suite of programs designed to enhance the efficiency of drug discovery including access to biological models as well as both small-molecule and secreted protein drug targets. In addition, Deltagen offers extensive target validation data in the areas of immunology and metabolic diseases. Deltagen's products and programs have been validated by customers and partners such as Eli Lilly & Co., GlaxoSmithKline, Merck & Co., Millennium Pharmaceuticals and Pfizer.

Deltagen’s unique systems biology approach is designed to help clear the first and major hurdle of drug target discovery: lead validation. Our high-throughput in vivo mammalian knockout technology enables us to identify and validate the utility of genomic targets within a living model at an extraordinary scale and speed. Using our proprietary tools, we believe we can uncover clinically relevant drug targets more efficiently and earlier in the discovery process.

The scientists in our Target Discovery Program have developed methods to discover the gene function of novel drug targets and to understand disease pathways as we strive to accelerate the development of meaningful, commercially promising small-molecule and secreted-protein therapies. Our proprietary technology platforms serve the drug discovery efforts of our pharmaceutical partners and customers.

Snapshot Information

June 27, 2003 Files Chapter 11 BK ~ Lexicon Genetics sues Deltagen over royalties
Nov 15, 2005 Court Approves reorganization
March 14, 2005 Lexicon and Deltagen Settle diputes, Deltagen pays 4Million cash payment
Sept 2005 NIH gives 3 year contract, valued up to $25 Million
Sept 2005 (CRL) Charles River Laboratorys becomes exclusive custodian of world wide distributor of Deltagens repository.
Sept 30 2005 NIH orders $5.16 Million worth of knockout mouse
Nov 15 2005 Court Approves, paying creditor claims 100% and equity preserved intact.
Nov 29 2005 Court Appointed Reorganization effective.
Dec 2005 CEO resigns - Lawrence Hill, VP I&L Robert Driscoll becomes CEO and President and Secretary
Dr. Winston Thomas - elected COO
Dr. Shera Kash - elected VPO
Dr. Driscoll, Mr. Hill, Dr. Chambon, Mr. Hernon - elected to BOD
-----------------------------------------------------------------------------------------------------------------
Jan 2006 NIH pays $1.93 Million
Mar 31 2006 Company closes Chapter 11 BK with all contested claims resolved.
Jan-Feb-Mar ~ brings in $1.8M - 431K net
$1.548M - expenses to salaries, 3rd-party royaty, patent prosecution, legal fees
Cash on hand $10.392 Million.
Jun 30 2006 $3.749 Million Revenue
NIH pays $3.2Million per 3 year contract
$0.500 Million Revenue in Access Fees
$1.4Million Net
Cash on hand $10.789Million
July 2006 Hire investment banking firm to assist strategic alternatives or sale of company.
Sept 30 2006 $0.970 Million Revenue
$0137 net
Cash on hand $11.993Million
Oct 2006 Deltagen enters agreement to 1 time buyout of DeltaBase collborators
Nov 2006 BOD terminate Investment Banking option.
Deltagen moves to new facilities: The Artium, 1900 South Norfolk St. Ste 105, San Mateo, Ca.
Dec 2006 Divy of .20 per share reduces cash by $7.7Million
Cash on hand $4.29Million


Corporate Headquarters
1031 Bing Street
San Carlos, CA 94070
Tel 650-569-5100

New Corporate Headquarters
effective - Jan 1, 2007
The Atrium
1900 South Norfolk Street, Suite 105,
San Mateo, CA 94403.


Products and Programs
Winston Thomas, PhD.
Chief Operating Officer
Tel 650-569-5412
deltaone@deltagen.com

What they do....
Deltagen’s unique systems biology approach is designed to help clear the first and major hurdle of drug target discovery: lead validation. Our high-throughput in vivo mammalian knockout technology enables us to identify and validate the utility of genomic targets within a living model at an extraordinary scale and speed. Using our proprietary tools, we believe we can uncover clinically relevant drug targets more efficiently and earlier in the discovery process.

Product Line
Since late 2005, Deltagen has had a collaboration with Charles River Laboratories of Wilmington, Massachusetts (NYSE: CRL). Charles River Laboratories, a global provider of solutions that advance the drug discovery and development process for the biopharmaceutical industry, is the exclusive custodian and worldwide distributor of Deltagen's repository of knockout mouse materials

Reference
http://www.criver.com/

Press Releases and Other Information
http://www.deltagen.com/pressreleases/pressreleases.html

OFFICERS

Robert J. Driscoll, J.D., Ph.D.
President and Chief Executive Officer

Robert Driscoll, J.D., Ph.D., President and Chief Executive Officer since 2005, formerly served as the company's Vice President, Intellectual Property & Legal Affairs from 2003 until 2005 and as Associate General Counsel. Prior to joining Deltagen in 1999, Dr. Driscoll was a patent and intellectual property attorney with the law firm of Pillsbury Madison & Sutro LLP. Dr. Driscoll received his Ph.D. in Chemistry from the California Institute of Technology and his J.D. from Loyola Law School. Dr. Driscoll also sits on the company's Board of Directors.

Winston Thomas, Ph.D.
Chief Operating Officer

Winston Thomas, Ph.D., Chief Operating Officer since November 2005, formerly served as the company's Vice President, Scientific Operations from 2003 until November 2005 and as Associate Director and Senior Director of Molecular Biology. Prior to joining Deltagen in 1999, Dr. Thomas was a Senior Scientist at Mercator Genetics, Inc. from 1993 to 1999 and was a postdoctoral fellow at Genentech. Dr. Thomas received his Ph.D. in Cellular and Developmental Biology from Harvard University and his B.Sc. from the University of Utah.

Daniel Ratto
Chief Financial Officer

Daniel Ratto, Chief Financial Officer since 2003, has over 20 years of experience in various financial positions. For the last 16 years, Mr. Ratto has worked as a consultant in the fields of turnarounds, bankruptcy, restructuring, accounting and finance, having worked for a wide variety of companies.

 

BOARD of DIRECTORS

Constantine E. Anagnostopoulos, Ph.D.

Constantine Anagnostopoulos is Deltagen's Chairman of the Board. Dr. Anagnostopoulos is a retired corporate officer of Monsanto Company, a former managing partner of Gateway Associates, a Missouri-based venture capital firm, and the recently retired lead director of Genzyme Corporation. At Monsanto he served as Director of Research, Head of the New Enterprise Division, General Manager of a number of operating divisions and Chairman, President and CEO of Monsanto Europe-Africa-Middle East. He presently sits on the board of five biopharmaceutical companies, including Dyax Corporation. Dr. Anagnostopoulos received his Ph.D. in Organic Chemistry from Harvard University and is a graduate of the Executive Program in Business Administration of Columbia University. He has served on the Presidential Council on Innovation.

Robert J. Driscoll, J.D., Ph.D.

Robert Driscoll is Deltagen's President, Secretary and Chief Executive Officer. Dr. Driscoll served previously as Deltagen's Vice President, Intellectual Property & Legal Affairs and Associate General Counsel. Prior to joining Deltagen, Dr. Driscoll was a patent and intellectual property attorney with the law firm of Pillsbury Madison & Sutro LLP. Dr. Driscoll received his Ph.D. in Chemistry from the California Institute of Technology and his J.D. from Loyola Law School.

Martin J. Hernon

Marty Hernon is a General Partner of Boston Millenia Partners. From 1994 to 1997, Mr. Hernon was a Principal at Boston Capital Ventures. Previously, he was Assistant General Counsel for Lifetime Corporation, an alternate site healthcare services business, and an attorney in the Business Department at Warner & Stackpole/Kirkpatrick & Lockhart, a Boston law firm. Mr. Hernon received a B.A. in Economics from Boston College, an M.A. in Economics from the University of Maryland and a J.D. from Georgetown University.

Thomas A. Penn, J.D., M.B.A.

Thomas Penn is a Partner of Meridian Venture Partners. From 1998 until 2000 Mr. Penn was a partner of Boston Millennia Partners. From 1994 until 1998, Mr. Penn served as President and Chief Executive Officer of Tektagen, Inc. Prior to joining Tektagen, Mr. Penn was President of Independence Ventures, Inc. Mr. Penn has served as President of the Pennsylvania Biotechnology Association and as Co-Chair of Pennsylvania's Technology 21 Biotechnology Network. Mr. Penn holds B.S. degrees from the Massachusetts Institute of Technology in Metallurgy and Materials Science and in Industrial Management, an M.B.A. from Stanford University, and a J.D. from the University of Pennsylvania.

William A. Scott, Ph.D.

William Scott is the former Chief Executive Officer of Physiome Sciences, where he served from 1997 to 1999. Prior to joining Physiome Sciences, Dr. Scott spent thirteen years with Bristol-Meyers Squibb where he held a number of management posts, including Senior Vice President of Exploratory and Drug Discovery Research. Dr. Scott has served on the boards of eight companies including CombiChem, Inc., and currently serves on the Boards of Atherogenics, Inc. and Avalon Pharmaceuticals, Inc. Dr. Scott holds a B.Sc. in Chemistry from the University of Illinois and a Ph.D. in Biochemistry from the California Institute of Technology. Dr. Scott is an Adjunct Professor at the Rockefeller University, where he has been affiliated since 1969.

SHARE STRUCTURE - O/S Approx. 39 mil.

DGEN institutional ownership:

2009-11-12 2009-09-30 13F-HR Everett Harris And Co Institution 6,182,188 No Change

http://www.mffais.com/dgen.pk


Top Institutional HoldersConcentration of Current % Held

Everett Harris & Co. 6.2M $494,575 +53% 16.0% Low
Wells Capital ... 5.5M $387,934 +47% 14.4% Moderate

http://data.cnbc.com/quotes/DGEN/tab/8


http://www.pinksheets.com/edgar/GetFilingHtml?FilingID=6348952



courtesy of Stock Charts:http://stockcharts.com


Disclaimer The members of this board do not recommend that you buy, sell, or hold any of the stocks listed on this board.

DGEN
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#333   Anyone know what happened today, why the huge drop? chetntam 11/11/14 03:45:40 PM
#332   I got a feeling about DGEN Popping soon! Dre77 05/13/14 01:09:59 PM
#331   DGEN major bounce could be on the way kranthikumar 11/27/13 09:52:43 AM
#330   Great post,just what i was looking for. Jeffbro 02/13/13 03:30:20 PM
#329   DGEN posted 1st qtr results on 5/22, but findit 06/11/12 03:29:56 PM
#328   Website up and running - bentenbio.com, no mention offtothemarket 02/14/12 07:43:22 PM
#327   still waiting for... something satelliteguy 10/11/11 03:07:29 PM
#326   aarrgghh satelliteguy 08/30/11 11:13:46 PM
#325   Second Quarter is out...more delays offtothemarket 08/30/11 07:44:36 PM
#324   Well, that sure took a nasty turn :) satelliteguy 08/29/11 10:34:34 PM
#323   BCIDemo site is down now. I spoke finbar99 08/29/11 12:24:46 PM
#322   Nice find. Let's keep an eye on satelliteguy 08/21/11 09:34:54 PM
#321   http://bcidemo.com/default.aspx# very interesting - especially the 'news' i finbar99 08/21/11 12:51:46 PM
#320   A sign of life! And your first satelliteguy 07/13/11 01:34:37 PM
#319   You may want to look at a couple offtothemarket 07/13/11 01:02:45 PM
#318   Agreed on all counts. Glad someone else satelliteguy 06/16/11 09:41:31 AM
#317   I put a call in to the company nsomniyak 06/15/11 08:17:48 PM
#316   Just keeping the flame alive. The company satelliteguy 06/15/11 07:23:05 PM
#315   I guess everyone else has moved on to satelliteguy 04/26/11 05:27:05 PM
#314   Another mostly silent month. zzzzzzz satelliteguy 03/09/11 05:01:21 PM
#313   Didn't realize you were in this one too. satelliteguy 02/13/11 11:17:03 PM
#312   Some vol finally. .05 flat. Vol 35 times findit 01/18/11 11:59:22 AM
#311   zzzzzz satelliteguy 01/08/11 01:52:04 AM
#310   shhhh - you might wake it up... nsomniyak 12/06/10 04:53:45 PM
#309   And then it went back to sleep again. satelliteguy 12/06/10 04:51:06 PM
#308   Saw that volume - very big for DGEN nsomniyak 11/06/10 10:19:12 PM
#307   No one talking here about the past week's satelliteguy 11/06/10 03:16:42 PM
#306   Don't quote me - I think around 65-ish? finbar99 10/01/10 04:55:57 PM
#305   how many shares does DGEN have outstanding? nsomniyak 10/01/10 04:22:40 PM
#304   I do believe that certain royalty rights with finbar99 10/01/10 03:17:07 PM
#303   >>you might not be aware that back in finbar99 10/01/10 03:14:37 PM
#302   As I've posted before, I've been in DGEN finbar99 10/01/10 03:01:35 PM
#301   There were obviously a few people who couldn't satelliteguy 09/30/10 03:34:02 PM
#300   DGEN - today's volume is almost 20x average volume nsomniyak 09/30/10 03:30:51 PM
#299   OT: yikes WZE also went goo goo goo, swampboots 09/30/10 02:31:34 PM
#298   Nope. Have not been in touch with satelliteguy 09/30/10 02:14:15 PM
#297   I noticed, and moving quickly. Any reason ksuave 09/30/10 02:02:57 PM
#296   Holy molly I can't belive it, have 55K swampboots 09/30/10 02:02:51 PM
#295   Shhh! Don't look now but DGEN has awakened. satelliteguy 09/30/10 01:55:32 PM
#294   I hope these guys are working on a ksuave 09/13/10 11:15:00 AM
#293   There's been some volume lately... time to wake satelliteguy 08/10/10 12:47:10 PM
#292   thanks; good value here w/cash position alone uw86 06/07/10 08:58:46 AM
#291   Thanks for the background. ksuave 06/04/10 06:04:27 PM
#290   Its cheap here trading at roughly 1/2 cash finbar99 06/04/10 03:51:08 PM
#289   Volume precedes price, no? ksuave 06/04/10 03:12:30 PM
#288   I don't believe there has been any change satelliteguy 06/04/10 10:47:41 AM
#287   are #shares o/s still around 40 million; thanks uw86 06/03/10 06:58:14 PM
#286   Nice find! Good to know things are satelliteguy 06/03/10 09:54:14 AM
#285   Benten got some space finbar99 06/02/10 05:40:51 PM
#284   Volume is great; price, not so much. ksuave 05/13/10 02:15:10 PM
PostSubject